Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management
Find out how Certara helped a small biotech achieve on-time IND and CTA submissions with…
CertaraAugust 18, 2025
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
CertaraAugust 13, 2025
Differences between eCTD 4.0 and eCTD 3.2.2 Submissions – What You Need to Know
Access our on-demand webinar to explore the key differences between eCTD 4.0 and eCTD 3.2.2.…
CertaraAugust 11, 2025
Certara Reports Second Quarter 2025 Financial Results
RADNOR, PA— August 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…
CertaraAugust 6, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator
Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…
CertaraAugust 5, 2025
